Alignment Healthcare Reports Third Quarter 2025 Results, Surpasses High-End of Guidance Across All Key Metrics
Alignment Healthcare (NASDAQ: ALHC) reported third quarter 2025 results and exceeded the high end of guidance across all key metrics on Oct 30, 2025. Q3 revenue was $993.7M (+43.5% YoY) and health plan membership reached ~229,600 (+25.9% YoY). Adjusted gross profit was $127.5M, adjusted EBITDA was $32.4M, and net income was $3.7M. The company said 100% of members are in plans rated 4 stars or higher for the second consecutive year, including two 5-star contracts and a 4.5-star contract.
Management raised full-year outlook and provided Q4 and FY2025 ranges: FY revenue $3.931B–3.946B, adjusted EBITDA $90M–98M, and Q4 revenue $995M–1.010B.
Alignment Healthcare (NASDAQ: ALHC) ha riportato i risultati del terzo trimestre 2025 e ha superato l’estremità superiore delle previsioni in tutti i principali indicatori il 30 ottobre 2025. Il fatturato del Q3 è stato di $993.7M (+43,5% su base annua) e l’iscrizione al piano sanitario ha raggiunto circa 229.600 (+25,9% su base annua). L’utile lordo rettificato è stato $127.5M, l’EBITDA rettificato è stato $32.4M, e l’utile netto è stato $3.7M. L’azienda ha dichiarato che il 100% dei membri è in piani valutati 4 stelle o superiori per il secondo anno consecutivo, includendo due contratti da 5 stelle e un contratto da 4,5 stelle.
La direzione ha alzato le previsioni per l’anno intero e ha fornito le gamme per Q4 e per FY2025: ricavi FY $3.931B–3.946B, EBITDA rettificato $90M–98M, e ricavi Q4 $995M–1.010B.
Alignment Healthcare (NASDAQ: ALHC) informó los resultados del tercer trimestre de 2025 y superó el extremo superior de las previsiones en todos los indicadores clave el 30 de octubre de 2025. Los ingresos del 3T fueron de $993.7M (+43.5% interanual) y la membresía del plan de salud alcanzó aproximadamente 229,600 (+25.9% interanual). El beneficio bruto ajustado fue de $127.5M, el EBITDA ajustado fue de $32.4M y el ingreso neto fue de $3.7M. La empresa indicó que el 100% de los miembros están en planes calificados con 4 estrellas o más por segundo año consecutivo, incluyendo dos contratos de 5 estrellas y un contrato de 4.5 estrellas.
La dirección elevó las perspectivas para el año completo y proporcionó rangos para el Q4 y FY2025: ingresos FY $3.931B–3.946B, EBITDA ajustado $90M–98M, y ingresos Q4 $995M–1.010B.
Alignment Healthcare (NASDAQ: ALHC)는 2025년 3분기 실적을 발표했고 2025년 10월 30일에 핵심 지표 전반에서 가이던스의 상단을 상회했습니다. 3분기 매출은 $993.7M으로 전년동기 대비 +43.5%였고 건강보험 플랜 회원 수는 약 229,600명으로 증가했습니다(+전년동기 대비 +25.9%). 조정된 총이익은 $127.5M, 조정된 EBITDA는 $32.4M, 순이익은 $3.7M였습니다. 회사는 회원의 100%가 4성급 이상으로 평가된 플랜에 속해 있으며 이는 2년 연속 달성으로, 5성급 두 개 계약과 4.5성급 계약을 포함한다고 밝혔습니다.
경영진은 연간 전망을 상향 조정하고 4분기(Q4) 및 FY2025 범위를 제시했습니다: FY 매출 $3.931B–3.946B, 조정된 EBITDA $90M–98M, 그리고 Q4 매출 $995M–1.010B.
Alignment Healthcare (NASDAQ: ALHC) a publié les résultats du troisième trimestre 2025 et a dépassé le niveau supérieur des prévisions sur tous les indicateurs clés le 30 octobre 2025. Le chiffre d’affaires T3 s’est élevé à $993.7M (+43,5% d’une année sur l’autre) et l’adhésion au plan de santé a atteint environ 229 600 (+25,9% d’une année sur l’autre). Le bénéfice brut ajusté s’est élevé à $127.5M, l’EBITDA ajusté à $32.4M, et le résultat net à $3.7M. La société a indiqué que 100% des membres sont dans des plans notés 4 étoiles ou plus pour la deuxième année consécutive, incluant deux contrats 5 étoiles et un contrat 4,5 étoiles.
La direction a relevé les perspectives pour l’année entière et fourni les fourchettes pour le Q4 et FY2025 : revenus FY $3.931B–3.946B, EBITDA ajusté $90M–98M, et revenus Q4 $995M–1.010B.
Alignment Healthcare (NASDAQ: ALHC) meldete die Ergebnisse des dritten Quartals 2025 und übertraf zum 30. Oktober 2025 bei allen zentralen Kennzahlen die obere Guidance. Umsatz Q3 betrug $993.7M (+43,5% YoY) und die Mitgliedschaft im Gesundheitsplan erreichte ca. 229,600 (+25,9% YoY). Das bereinigte Bruttoergebnis war $127.5M, das bereinigte EBITDA $32.4M und der Nettogewinn $3.7M. Das Unternehmen sagte, dass 100% der Mitglieder in Plänen mit 4 Sternen oder mehr für das zweite aufeinanderfolgende Jahr sind, einschließlich zwei 5-Sterne-Verträgen und eines 4,5-Sterne-Vertrags.
Das Management hob die Volljahresausblicke an und gab Bereiche für Q4 und FY2025 bekannt: FY-Umsatz $3.931B–3.946B, bereinigtes EBITDA $90M–$98M, und Q4-Umsatz $995M–$1.010B.
Alignment Healthcare (NASDAQ: ALHC) أبلغت عن نتائج الربع الثالث من 2025 وتجاوزت الحد الأعلى للتوجيه عبر جميع المقاييس الأساسية في 30 أكتوبر 2025. إيرادات الربع الثالث بلغت $993.7M (+43.5% سنوياً) وبلغ عدد أعضاء خطة التأمين الصحي نحو 229,600 (+25.9% سنوياً). بلغت الربح الإجمالي المعدّل $127.5M، وبلغ EBITDA المعدّل $32.4M، وصافي الدخل $3.7M. قالت الشركة أن 100% من الأعضاء في خطط مُصنَّفة بـ4 نجوم فأكثر للسنة الثانية على التوالي، بما في ذلك عقدان بخمس نجوم وعقد واحد 4.5 نجمة.
رفعت الإدارة التوقعات للسنة الكاملة ووفرت نطاقات لـ Q4 وFY2025: عائدات FY $3.931B–3.946B، EBITDA المعدّل $90M–98M، وعائدات Q4 $995M–1.010B.
- Revenue +43.5% YoY to $993.7M
- Membership +25.9% YoY to ~229,600 members
- Adjusted EBITDA $32.4M in Q3
- 100% of members in 4-star or higher plans (two 5-star contracts)
- Medical benefits ratio 87.2% based on adjusted gross profit
- Selling, general & administrative $110.0M in Q3 (includes $14.5M equity comp)
- Q4 adjusted EBITDA guidance implies a loss range of $(9M) to $(1M)
Insights
Strong operational beat: membership, revenue and margin guidance all raised; quality ratings remain excellent.
Membership grew to approximately 229,600, up
The profitability signal is specific: adjusted gross profit was
Key dependencies and risks include continued enrollment growth within the guided range (
- Reports Q3 revenue of
$993.7 million , up43.5% year-over-year - Beats high end of third quarter guidance and raises full-year outlook across all key metrics: membership, revenue, adjusted gross profit and adjusted EBITDA
- Has
100% of members in plans rated 4 stars or higher for second consecutive year in 2026, including two 5-star contracts in Nevada and North Carolina and a 4.5-star contract in Texas
ORANGE, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Alignment Healthcare, Inc. (NASDAQ: ALHC), today reported financial results for its third quarter ended September 30, 2025.
“Our third quarter results mark the third consecutive quarter in which we surpassed the high end of our guidance across all key metrics,” said John Kao, founder and CEO. “These outcomes reinforce the strength and scalability of our care model, which continues to deliver consistent results across our markets. With
Third Quarter 2025 Financial Highlights
All comparisons, unless otherwise noted, are to the three months ended September 30, 2024.
- Health plan membership at the end of the quarter was approximately 229,600, up
25.9% year-over-year - Total revenue was
$993.7 million , up43.5% year-over-year - Adjusted gross profit* was
$127.5 million and income from operations was$7.7 million - Adjusted gross profit excludes depreciation and amortization of
$8.0 million and selling, general, and administrative expenses of$110.0 million (which includes$14.5 million of equity-based compensation). Adjusted gross profit also excludes$0.01 million of depreciation expense and an additional$1.8 million of equity-based compensation recorded within medical expenses - Medical benefits ratio based on adjusted gross profit was
87.2%
- Adjusted gross profit excludes depreciation and amortization of
- Adjusted EBITDA* was
$32.4 million and net income was$3.7 million
* Please see "Third Quarter 2025 Non-GAAP Reconciliation Tables" below for more information on the non-GAAP financial measures reported here as supplemental information.
Outlook for Fourth Quarter and Fiscal Year 2025
| Three Months Ending December 31, 2025 | Twelve Months Ending December 31, 2025 | ||||
| $ Millions | Low | High | Low | High | |
| Health Plan Membership | 232,500 | 234,500 | 232,500 | 234,500 | |
| Revenue | |||||
| Adjusted Gross Profit(1) | |||||
| Adjusted EBITDA(1) | |||||
_______________________
(1) Adjusted gross profit and adjusted EBITDA are non-GAAP financial measures presented as supplemental disclosure. We cannot provide estimated ranges for the most directly comparable GAAP measures without unreasonable efforts because of the uncertainty around certain items that may impact such GAAP measures, including equity-based compensation expense and depreciation and amortization, that are not within our control or cannot be reasonably predicted. See “Third Quarter 2025 Non-GAAP Reconciliation Tables” for additional information.
Third Quarter 2025 Non-GAAP Reconciliation Tables
Adjusted Gross Profit(1) is reconciled as follows:
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| (dollars in thousands) | ||||||||||||||||
| Income (loss) from operations | $ | 7,681 | $ | (19,522 | ) | $ | 25,036 | $ | (79,010 | ) | ||||||
| Add back: | ||||||||||||||||
| Equity-based compensation (medical expenses) | 1,775 | 1,489 | 4,521 | 3,384 | ||||||||||||
| Depreciation (medical expenses) | 8 | 46 | 74 | 144 | ||||||||||||
| Restructuring costs (medical expenses)(2) | — | — | — | 796 | ||||||||||||
| Depreciation and amortization(3) | 7,977 | 7,640 | 22,574 | 20,110 | ||||||||||||
| Selling, general, and administrative expenses | 110,015 | 90,871 | 317,643 | 269,246 | ||||||||||||
| Total add back | 119,775 | 100,046 | 344,812 | 293,680 | ||||||||||||
| Adjusted gross profit | $ | 127,456 | $ | 80,524 | $ | 369,848 | $ | 214,670 | ||||||||
(1) Adjusted gross profit is a non-GAAP financial measure that is presented as supplemental disclosure, that we define as income (loss) from operations before depreciation and amortization, clinical equity-based compensation expense, clinical restructuring costs and selling, general, and administrative expenses.
(2) Represents severance and related costs incurred as part of a corporate restructuring designed to streamline our organizational structure and drive operational efficiencies.
(3) Amortization expense for the nine months ended September 30, 2025 includes
Adjusted EBITDA(1) is reconciled as follows:
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| (dollars in thousands) | ||||||||||||||||
| Net income (loss) | $ | 3,729 | $ | (26,429 | ) | $ | 10,028 | $ | (97,007 | ) | ||||||
| Less: Net loss attributable to noncontrolling interest | — | (16 | ) | (254 | ) | (63 | ) | |||||||||
| Adjustments: | ||||||||||||||||
| Interest expense | 3,950 | 6,937 | 11,850 | 18,055 | ||||||||||||
| Depreciation and amortization(2) | 7,985 | 7,686 | 22,648 | 20,254 | ||||||||||||
| Income taxes | 2 | (8 | ) | 3,247 | 14 | |||||||||||
| Equity-based compensation(3) | 16,227 | 17,258 | 48,967 | 54,896 | ||||||||||||
| Acquisition expenses(4) | — | 14 | — | 26 | ||||||||||||
| Litigation costs(5) | 546 | 456 | 1,608 | 1,177 | ||||||||||||
| Loss on ROU assets(6) | — | — | — | 143 | ||||||||||||
| Gain on sale of property and equipment | — | (8 | ) | (72 | ) | (8 | ) | |||||||||
| Restructuring costs(7) | — | — | — | 2,363 | ||||||||||||
| Adjusted EBITDA | $ | 32,439 | $ | 5,922 | $ | 98,530 | $ | (24 | ) | |||||||
(1) Adjusted EBITDA is a non-GAAP financial measure that is presented as supplemental disclosure, that we define as net income (loss) before interest expense, income taxes, depreciation and amortization expense, certain litigation costs, gains or losses on right of use ("ROU") assets, gains or losses on sale of property and equipment, restructuring costs and equity-based compensation expense.
(2) Amortization expense for the nine months ended September 30, 2025 includes
(3) Represents equity-based compensation related to grants made in the applicable year.
(4) Represents acquisition-related fees, such as legal and advisory fees, that are non-capitalizable.
(5) Represents litigation costs considered outside of the ordinary course of business based on the following considerations which we assess regularly: (i) the frequency of similar cases that have been brought to date, or are expected to be brought within two years, (ii) complexity of the case, (iii) nature of the remedies sought, (iv) litigation posture of the Company, (v) counterparty involved, and (vi) the Company's overall litigation strategy.
(6) Represents gains or losses related to ROU assets that were terminated or subleased in the respective period.
(7) Represents severance and related costs incurred as part of a corporate restructuring designed to streamline our organizational structure and drive operational efficiencies.
Conference Call Details
The company will host a conference call at 5 p.m. EDT today to discuss these results and management’s outlook for future financial and operational performance. A live audio webcast will be available online at https://ir.alignmenthealth.com/. At the start of the conference call, participants may access the webcast at the following link: https://edge.media-server.com/mmc/p/ov96m6yi. A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call, at the same web links, and will remain available for approximately 12 months.
About Alignment Health
Alignment Health is championing a new path in senior care that empowers members to age well and live their most vibrant lives. A consumer brand name of Alignment Healthcare (NASDAQ: ALHC), Alignment Health’s mission-focused team makes high-quality, low-cost care a reality for its Medicare Advantage members every day. Based in California, the company partners with nationally recognized and trusted local providers to deliver coordinated care, powered by its customized care model, 24/7 concierge care team and purpose-built technology, AVA®. As it expands its offerings and grows its national footprint, Alignment upholds its core values of leading with a serving heart and putting the senior first. For more information, visit www.alignmenthealth.com.
Forward-Looking Statements
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, as amended. These forward-looking statements include statements regarding our future growth and our financial outlook for the quarter and year ending December 31, 2025. Forward-looking statements are subject to risks and uncertainties and are based on assumptions that may prove to be inaccurate, which could cause actual results to differ materially from those expected or implied by the forward-looking statements. Actual results may differ materially from the results predicted, and reported results should not be considered as an indication of future performance. Important risks and uncertainties that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: our ability to attract new members and enter new markets, including the need for certain governmental approvals; our ability to maintain a high rating for our plans on the Five Star Quality Rating System; our ability to develop and maintain satisfactory relationships with care providers that service our members; risks associated with being a government contractor, including potential federal reductions in MA funding; changes in laws and regulations applicable to our business model; risks related to our indebtedness; changes in market or industry conditions and receptivity to our technology and services; results of litigation or a security incident; and the impact of shortages of qualified personnel and related increases in our labor costs. For a detailed discussion of the risk factors that could affect our actual results, please refer to the risk factors identified in our Annual Report on Form 10-K for the year ended December 31, 2024, and the other periodic reports we file with the SEC. All information provided in this release and in the attachments is as of the date hereof, and we undertake no duty to update or revise this information unless required by law.
Condensed Consolidated Balance Sheets (in thousands, except par value and share amounts) (Unaudited) | ||||||||
| September 30, 2025 | December 31, 2024 | |||||||
| Assets | ||||||||
| Current Assets: | ||||||||
| Cash and cash equivalents | $ | 618,067 | $ | 432,859 | ||||
| Accounts receivable (less allowance for credit losses of | 219,837 | 153,904 | ||||||
| Investments - current | 26,013 | 37,791 | ||||||
| Prepaid expenses and other current assets | 121,407 | 37,084 | ||||||
| Total current assets | 985,324 | 661,638 | ||||||
| Property and equipment, net | 67,017 | 67,139 | ||||||
| Right of use asset, net | 7,338 | 7,818 | ||||||
| Goodwill | 32,060 | 34,826 | ||||||
| Intangible Assets, net | 4,550 | 4,550 | ||||||
| Other assets | 6,325 | 6,092 | ||||||
| Total assets | $ | 1,102,614 | $ | 782,063 | ||||
| Liabilities and Stockholders' Equity | ||||||||
| Current Liabilities: | ||||||||
| Medical expenses payable | $ | 528,796 | $ | 289,788 | ||||
| Accounts payable and accrued expenses | 34,009 | 22,126 | ||||||
| Accrued compensation | 48,280 | 39,931 | ||||||
| Total current liabilities | 611,085 | 351,845 | ||||||
| Long-term debt, net of debt issuance costs | 322,736 | 321,428 | ||||||
| Long-term portion of lease liabilities | 6,922 | 7,835 | ||||||
| Total liabilities | 940,743 | 681,108 | ||||||
| Stockholders' Equity: | ||||||||
| Preferred stock, $.001 par value; 100,000,000 shares authorized as of September 30, 2025 and December 31, 2024, respectively; no shares issued and outstanding as of September 30, 2025 and December 31, 2024 | — | — | ||||||
| Common stock, $.001 par value; 1,000,000,000 shares authorized as of September 30, 2025 and December 31, 2024; 199,988,515 and 191,778,639 shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively | 200 | 192 | ||||||
| Additional paid-in capital | 1,159,682 | 1,107,952 | ||||||
| Accumulated deficit | (998,011 | ) | (1,008,293 | ) | ||||
| Total Alignment Healthcare, Inc. stockholders' equity | 161,871 | 99,851 | ||||||
| Noncontrolling interest | — | 1,104 | ||||||
| Total stockholders' equity | 161,871 | 100,955 | ||||||
| Total liabilities and stockholders' equity | $ | 1,102,614 | $ | 782,063 | ||||
| Condensed Consolidated Statements of Operations (in thousands, except per share amounts) (Unaudited) | ||||||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| Revenues: | ||||||||||||||||
| Earned premiums | $ | 983,681 | $ | 684,496 | $ | 2,907,927 | $ | 1,980,146 | ||||||||
| Other | 10,014 | 7,937 | 27,988 | 22,174 | ||||||||||||
| Total revenues | 993,695 | 692,433 | 2,935,915 | 2,002,320 | ||||||||||||
| Expenses: | ||||||||||||||||
| Medical expenses | 868,022 | 613,444 | 2,570,662 | 1,791,974 | ||||||||||||
| Selling, general, and administrative expenses | 110,015 | 90,871 | 317,643 | 269,246 | ||||||||||||
| Depreciation and amortization | 7,977 | 7,640 | 22,574 | 20,110 | ||||||||||||
| Total expenses | 986,014 | 711,955 | 2,910,879 | 2,081,330 | ||||||||||||
| Income (loss) from operations | 7,681 | (19,522 | ) | 25,036 | (79,010 | ) | ||||||||||
| Other expenses: | ||||||||||||||||
| Interest expense | 3,950 | 6,937 | 11,850 | 18,055 | ||||||||||||
| Other income, net | — | (22 | ) | (89 | ) | (72 | ) | |||||||||
| Total other expense | 3,950 | 6,915 | 11,761 | 17,983 | ||||||||||||
| Income (loss) before income taxes | 3,731 | (26,437 | ) | 13,275 | (96,993 | ) | ||||||||||
| Provision (benefit) for income taxes | 2 | (8 | ) | 3,247 | 14 | |||||||||||
| Net income (loss) | $ | 3,729 | $ | (26,429 | ) | $ | 10,028 | $ | (97,007 | ) | ||||||
| Less: Net loss attributable to noncontrolling interest | — | (16 | ) | (254 | ) | (63 | ) | |||||||||
| Net income (loss) attributable to Alignment Healthcare, Inc. | $ | 3,729 | $ | (26,413 | ) | $ | 10,282 | $ | (96,944 | ) | ||||||
| Net income (loss) per share attributable to Alignment Healthcare, Inc.: | ||||||||||||||||
| Basic | 0.02 | (0.14 | ) | 0.05 | (0.51 | ) | ||||||||||
| Diluted | 0.02 | (0.14 | ) | 0.05 | (0.51 | ) | ||||||||||
| Weighted-average common shares outstanding: | ||||||||||||||||
| Basic | 199,026,808 | 191,361,283 | 197,007,141 | 190,423,014 | ||||||||||||
| Diluted | 208,927,980 | 191,361,283 | 208,439,200 | 190,423,014 | ||||||||||||
| Condensed Consolidated Statements of Cash Flows (in thousands) (Unaudited) | ||||||||
| Nine Months Ended September 30, | ||||||||
| 2025 | 2024 | |||||||
| Operating Activities: | ||||||||
| Net income (loss) | $ | 10,028 | $ | (97,007 | ) | |||
| Adjustments to reconcile net income (loss) to net cash provided by operating activities: | ||||||||
| Provision for credit loss | 548 | 123 | ||||||
| Loss on right of use assets | — | 135 | ||||||
| Gain on sale of property and equipment | (72 | ) | (8 | ) | ||||
| Depreciation and amortization | 22,648 | 20,254 | ||||||
| Amortization-investment discount | (1,041 | ) | (2,084 | ) | ||||
| Amortization-debt issuance costs | 1,321 | 978 | ||||||
| Equity-based compensation | 48,967 | 54,896 | ||||||
| Non-cash lease expense | 1,178 | 1,360 | ||||||
| Changes in operating assets and liabilities: | ||||||||
| Accounts receivable | (66,451 | ) | (19,226 | ) | ||||
| Prepaid expenses and other current assets | (84,326 | ) | (8,809 | ) | ||||
| Other assets | (47 | ) | 77 | |||||
| Medical expenses payable | 239,008 | 91,726 | ||||||
| Accounts payable and accrued expenses | 11,180 | 2,835 | ||||||
| Deferred premium revenue | 5 | (116 | ) | |||||
| Accrued compensation | 8,349 | (161 | ) | |||||
| Lease liabilities | (993 | ) | (1,492 | ) | ||||
| Net cash provided by operating activities | 190,302 | 43,481 | ||||||
| Investing Activities: | ||||||||
| Purchase of investments | (45,194 | ) | (75,524 | ) | ||||
| Sale of property and equipment | 75 | 14 | ||||||
| Maturities of investments | 57,995 | 152,755 | ||||||
| Sale of business | 1,065 | — | ||||||
| Acquisition of property and equipment | (21,752 | ) | (32,134 | ) | ||||
| Net cash (used in) provided by investing activities | (7,811 | ) | 45,111 | |||||
| Financing Activities: | ||||||||
| Proceeds from long-term debt | — | 50,000 | ||||||
| Payment of employment taxes related to release of restricted stock | — | (350 | ) | |||||
| Debt issuance costs | (26 | ) | (512 | ) | ||||
| Proceeds from stock option exercises | 2,771 | — | ||||||
| Contributions from noncontrolling interest holders | — | 15 | ||||||
| Net cash provided by financing activities | 2,745 | 49,153 | ||||||
| Net increase in cash | 185,236 | 137,745 | ||||||
| Cash, cash equivalents and restricted cash at beginning of period | 434,942 | 204,954 | ||||||
| Cash, cash equivalents and restricted cash at end of period | $ | 620,178 | $ | 342,699 | ||||
| Supplemental disclosure of cash flow information: | ||||||||
| Cash paid for interest | $ | 6,740 | $ | 15,602 | ||||
| Supplemental non-cash investing and financing activities: | ||||||||
| Acquisition of property in accounts payable | $ | 79 | $ | 112 | ||||
The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the condensed consolidated balance sheets to the total above:
| September 30, 2025 | September 30, 2024 | |||||||
| Cash and cash equivalents | $ | 618,067 | $ | 340,300 | ||||
| Restricted cash in other assets | 2,111 | 2,399 | ||||||
| Total | $ | 620,178 | $ | 342,699 | ||||
Non-GAAP Financial Measures
Certain of these financial measures are considered “non-GAAP” financial measures within the meaning of Item 10 of Regulation S-K promulgated by the SEC. We believe that non-GAAP financial measures provide an additional way of viewing aspects of our operations that, when viewed with the GAAP results, provide a more complete understanding of our results of operations and the factors and trends affecting our business. These non-GAAP financial measures are also used by our management to evaluate financial results and to plan and forecast future periods. However, non-GAAP financial measures should be considered as a supplement to, and not as a substitute for, or superior to, the corresponding measures calculated in accordance with GAAP. Non-GAAP financial measures used by us may differ from the non-GAAP measures used by other companies, including our competitors. To supplement our consolidated financial statements presented on a GAAP basis, we disclose the following non-GAAP measures: Medical Benefits Ratio, Adjusted EBITDA and Adjusted Gross Profit as these are performance measures that our management uses to assess our operating performance. Because these measures facilitate internal comparisons of our historical operating performance on a more consistent basis, we use these measures for business planning purposes and in evaluating acquisition opportunities.
Adjusted EBITDA
Adjusted EBITDA is a non-GAAP financial measure that we define as net income (loss) before interest expense, income taxes, depreciation and amortization expense, certain litigation costs, gains or losses on right of use ("ROU") assets, gains or losses on sale of property and equipment, restructuring costs and equity-based compensation expense.
Adjusted EBITDA should not be considered in isolation of, or as an alternative to, measures prepared in accordance with GAAP. There are a number of limitations related to the use of Adjusted EBITDA in lieu of net income (loss), which is the most directly comparable financial measure calculated in accordance with GAAP.
Our use of the term Adjusted EBITDA may vary from the use of similar terms by other companies in our industry and accordingly may not be comparable to similarly titled measures used by other companies.
Medical Benefits Ratio (MBR)
We calculate our MBR by dividing total medical expenses, excluding depreciation, equity-based compensation and clinical restructuring costs, by total revenues in a given period.
Adjusted Gross Profit
Adjusted gross profit is a non-GAAP financial measure that we define as income (loss) from operations before depreciation and amortization, clinical equity-based compensation expense, clinical restructuring costs and selling, general, and administrative expenses.
Adjusted gross profit should not be considered in isolation of, or as an alternative to, measures prepared in accordance with GAAP. There are a number of limitations related to the use of adjusted gross profit in lieu of income (loss) from operations, which is the most directly comparable financial measure calculated in accordance with GAAP.
Our use of the term adjusted gross profit may vary from the use of similar terms by other companies in our industry and accordingly may not be comparable to similarly titled measures used by other companies.
Investor Contact
Harrison Zhuo
hzhuo@ahcusa.com
Media Contact
Priya Shah
mPR, Inc. for Alignment Health
alignment@mpublicrelations.com
FAQ
What were Alignment Healthcare's Q3 2025 revenue and membership (ALHC)?
How did ALHC perform on adjusted EBITDA and net income in Q3 2025?
What FY2025 revenue and adjusted EBITDA guidance did Alignment Healthcare provide?
What does Alignment's 4-star+ plan coverage mean for ALHC members in 2026?
What is the company's Q4 2025 revenue and adjusted gross profit guidance (ALHC)?
Are there cost or margin areas investors should watch after ALHC's Q3 2025 report?
